Home » USA Broker Ratings » Agilent Technologies – Consensus Indicates Potential -1.6% Downside
Agilent Technologies

Agilent Technologies – Consensus Indicates Potential -1.6% Downside

Agilent Technologies with ticker code (A) have now 14 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between $110.00 and $88. and has a mean target at $103.64. Now with the previous closing price of $105.32 this is indicating there is a potential downside of -1.6%. The day 50 moving average is $100.53 and the 200 day MA is $90.22. The company has a market cap of $32,696m. Company Website: http://www.agilent.com

Agilent Technologies provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. The Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, and software as a service, as well as asset management and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer’s representatives, and electronic commerce. The company was founded in 1999 and is headquartered in Santa Clara, California.

Join us on our new LinkedIn page

Follow us on LinkedIn